SMARCA4 and anaplastic large cell lymphoma: Future development of pharmacological agents targeting BRG1 may offer novel therapeutic strategies for anaplastic large-cell lymphoma patients, especially in scenarios where resistance to chemotherapy presents a significant challenge.